Health- and vision-related quality of life in patients with ocular hypertension or primary open-angle glaucoma

Ophthalmologica

Volumn 229, Issue 4, 2013, Pages 227-234

  Wolfram, Christian ^a   Lorenz, Katrin ^a   Breitscheidel, Lusine ^b   Verboven, Yves ^c   Pfeiffer, Norbert ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b HEOR   (Germany)

^c Alcon Research Ltd   (Belgium)

Author keywords

Germany; Glaucoma; Patient reported outcomes; Quality of life

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; PROSTAGLANDIN DERIVATIVE;

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; COMORBIDITY; CROSS-SECTIONAL STUDY; DESCRIPTIVE RESEARCH; DISEASE COURSE; DISEASE SEVERITY; DRIVING ABILITY; FEMALE; HEALTH UTILITY INDEX 3; HUMAN; INTRAOCULAR HYPERTENSION; LOW LEVEL LASER THERAPY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NATIONAL EYE INSTITUTE VISUL FUNCTION QUESTIONNAIRE; OPEN ANGLE GLAUCOMA; PERCEPTION; QUALITY OF LIFE; QUALITY OF LIFE INDEX; SOCIAL ASPECT; AGED; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; FOLLOW UP; HEALTH STATUS; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SICKNESS IMPACT PROFILE; VISUAL ACUITY; VISUAL FIELD; AGE; DISEASE CLASSIFICATION; EYE DISEASE ASSESSMENT; GERMANY; HEALTH UTILITY INDEX; NATIONAL EYE INSTITUTE VISUAL FUNCTION QUESTIONNAIRE; PERIPHERAL VISION; SEX DIFFERENCE; UNIVERSITY HOSPITAL;

AGED; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; OCULAR HYPERTENSION; QUALITY OF LIFE; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SICKNESS IMPACT PROFILE; VISUAL ACUITY; VISUAL FIELDS;

EID: 84876458095     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000350553     Document Type: Article

References (42)

1. Buch H, et al: The prevalence and causes of bilateral and unilateral blindness in an elderly urban Danish population. The Copenhagen City Eye Study. Acta Ophthalmol Scand 2001; 79: 441-449.
2. Klaver CC, et al: Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 1998; 116: 653-658.
3. Quigley HA, Broman AT: The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90: 262-267.
4. Thygesen J, et al: Late-stage, primary openangle glaucoma in Europe: social and health care maintenance costs and quality of life of patients from 4 countries. Curr Med Res Opin 2008; 24: 1763-1770.
5. Dietlein TS, Hermann MM, Jordan JF: The medical and surgical treatment of glaucoma. Dtsch Arztebl Int 2009; 106: 597-605, quiz 606.
6. European Glaucoma Society (EGS): Terminology and Guidelines for Glaucoma, ed 3. 2008.
7. Friedman DS, et al: Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004; 122: 532-538.
8. Leske MC, et al: Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. Ophthalmology 2008; 115: 85-93.
9. Tielsch JM, et al: Family history and risk of primary open angle glaucoma. The Baltimore Eye Survey. Arch Ophthalmol 1994; 112: 69-73.
10. Tielsch JM, et al: Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA 1991; 266: 369-374.
11. Leske MC, et al: Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007; 114: 1965-1972.
12. Topouzis F, et al: Factors associated with undiagnosed open-angle glaucoma: the Thessaloniki Eye Study. Am J Ophthalmol 2008; 145: 327-335.
13. Weinreb RN, Kaufman PL: The glaucoma research community and FDA look to the future: a report from the NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci 2009; 50: 1497-1505.
14. Quigley HA: Number of people with glaucoma worldwide. Br J Ophthalmol 1996; 80: 389-393.
15. Henahan S: European Glaucoma Society Congress Report: new paradigm for glaucoma management. Eurotimes 2011.
16. Dietlein TS: Glaucoma in the aged-barriers to understanding and compliance (article in German). Ophthalmologe 2006; 103: 755-758.
17. Gupta V, et al: Utility values among glaucoma patients: an impact on the quality of life. Br J Ophthalmol 2005; 89: 1241-1244.
18. Kobelt G, et al: Cost-effectiveness analysis in glaucoma: what drives utility? Results from a pilot study in Sweden. Acta Ophthalmol Scand 2006; 84: 363-371.
19. Freeman EE, et al: Glaucoma and quality of life: the Salisbury Eye Evaluation. Ophthalmology 2008; 115: 233-238.
20. Hirneiss C, et al: Health-economic aspects of glaucoma screening (article in German). Ophthalmologe 2010; 107: 143-149.
21. Mills T, et al: Quality of life in glaucoma and three other chronic diseases: a systematic literature review. Drugs Aging 2009; 26: 933-950.
22. Warrian KJ, Altangerel U, Spaeth GL: Performance-based measures of visual function. Surv Ophthalmol 2010; 55: 146-161.
23. Felder-Puig R, et al: German cross-cultural adaptation of the Health Utilities Index and its application to a sample of childhood cancer survivors. Eur J Pediatr 2000; 159: 283-288.
24. Furlong WJ, et al: The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 2001; 33: 375-384.
25. Drummond M: Introducing economic and quality of life measurements into clinical studies. Ann Med 2001; 33: 344-349.
26. Horsman J, et al: The Health Utilities Index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes 2003; 1: 54.
27. College voor zorgverzekeringen (Health care insurance board): Guidelines for Pharmacoeconomic Research. Diemen, 2006.
28. National Institute for Health and Clinical Excellence: Guide to the Methods of Technology Appraisal. 2008.
29. Mangione CM, et al: Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2001; 119: 1050-1058.
30. Che Hamzah J, et al: Choosing appropriate patient-reported outcomes instrument for glaucoma research: a systematic review of vision instruments. Qual Life Res 2011; 20: 1141-1158.
31. Vandenbroeck S, et al: Patient-reported outcomes (PRO's) in glaucoma: a systematic review. Eye (Lond) 2011; 25: 555-577.
32. Statistics Canada: Canadian Community Health Survey 2005, Cycle 3. 1. Public Use Microdata File User Guide. Ottawa: Statistics Canada, 2006.
33. Stein JD: Disparities between ophthalmologists and their patients in estimating quality of life. Curr Opin Ophthalmol 2004; 15: 238-243.
34. Aspinall PA, et al: Evaluation of quality of life and priorities of patients with glaucoma. Invest Ophthalmol Vis Sci 2008; 49: 1907-1915.
35. Ramulu P: Glaucoma and disability: which tasks are affected, and at what stage of disease? Curr Opin Ophthalmol 2009; 20: 92-98.
36. van Gestel A, et al: The relationship between visual field loss in glaucoma and health-related quality-of-life. Eye (Lond) 2010; 24: 1759-1769.
37. Nelson P, et al: Quality of life in glaucoma and its relationship with visual function. J Glaucoma 2003; 12: 139-150.
38. Sawka AM, et al: Health-related quality of life measurements in elderly Canadians with osteoporosis compared to other chronic medical conditions: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 2005; 16: 1836-1840.
39. Wu SY, et al: Impact of glaucoma, lens opacities, and cataract surgery on visual functioning and related quality of life: the Barbados Eye Studies. Invest Ophthalmol Vis Sci 2008; 49: 1333-1338.
40. Hyman LG, et al: Treatment and vision-related quality of life in the early manifest glaucoma trial. Ophthalmology 2005; 112: 1505-1513.
41. Nordmann JP, et al: Vision related quality of life and topical glaucoma treatment side effects. Health Qual Life Outcomes 2003; 1: 75.
42. Jampel HD, et al: Depression and mood indicators in newly diagnosed glaucoma patients. Am J Ophthalmol 2007; 144: 238-244.